Literature DB >> 22441896

The GP2 peptide: a HER2/neu-based breast cancer vaccine.

Kevin S Clive1, Josh A Tyler, G Travis Clifton, Jarrod P Holmes, Sathibalan Ponniah, George E Peoples, Elizabeth A Mittendorf.   

Abstract

Preclinical studies suggest that GP2, a HER2/neu-derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2-based vaccines are safe and effective in stimulating peptide-specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients. This article reviews initial studies characterizing GP2, clinical trials investigating GP2-based vaccines, and novel immunotherapy strategies incorporating GP2 in combination with other peptides or with the monoclonal antibody trastuzumab.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22441896     DOI： 10.1002/jso.21723

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  17 in total

1.  Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors.

Authors:  Kevin Cronin; Hernando Escobar; Karoly Szekeres; Eduardo Reyes-Vargas; Alan L Rockwood; Mark C Lloyd; Julio C Delgado; George Blanck
Journal:  Hum Vaccin Immunother       Date:  2013-01-17       Impact factor: 3.452

Review 2.  Vaccination strategies for neuro-oncology.

Authors:  John H Sampson; Duane A Mitchell
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 3.  The immune system and inflammation in breast cancer.

Authors:  Xinguo Jiang; David J Shapiro
Journal:  Mol Cell Endocrinol       Date:  2013-06-19       Impact factor: 4.102

Review 4.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

5.  The molecular basis of breast cancer pathological phenotypes.

Authors:  Yujing J Heng; Susan C Lester; Gary Mk Tse; Rachel E Factor; Kimberly H Allison; Laura C Collins; Yunn-Yi Chen; Kristin C Jensen; Nicole B Johnson; Jong Cheol Jeong; Rahi Punjabi; Sandra J Shin; Kamaljeet Singh; Gregor Krings; David A Eberhard; Puay Hoon Tan; Konstanty Korski; Frederic M Waldman; David A Gutman; Melinda Sanders; Jorge S Reis-Filho; Sydney R Flanagan; Deena Ma Gendoo; Gregory M Chen; Benjamin Haibe-Kains; Giovanni Ciriello; Katherine A Hoadley; Charles M Perou; Andrew H Beck
Journal:  J Pathol       Date:  2016-12-29       Impact factor: 7.996

Review 6.  Immunotherapy for the treatment of breast cancer.

Authors:  Brenda Ernst; Karen S Anderson
Journal:  Curr Oncol Rep       Date:  2015-02       Impact factor: 5.075

7.  Racially restricted contribution of immunoglobulin Fcγ and Fcγ receptor genotypes to humoral immunity to human epidermal growth factor receptor 2 in breast cancer.

Authors:  J P Pandey; A M Namboodiri; E Kistner-Griffin; M Iwasaki; Y Kasuga; G S Hamada; S Tsugane
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

Review 8.  Peptide mimotopes alter T cell function in cancer and autoimmunity.

Authors:  Jill E Slansky; Maki Nakayama
Journal:  Semin Immunol       Date:  2020-03-20       Impact factor: 11.130

9.  Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?

Authors:  Anne C Armstrong; David E Gilham
Journal:  Breast Cancer Res       Date:  2012-05-30       Impact factor: 6.466

10.  Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines.

Authors:  Shuko Saku; Uhi Toh; Yuko Takao; Sayaka Sakurai; Akira Yamada; Shigeki Shichijo; Kyogo Itoh; Yoshito Akagi
Journal:  Exp Ther Med       Date:  2021-06-25       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.